UY25050A1 - Metodo de tratamiento para diabetes mellitus - Google Patents
Metodo de tratamiento para diabetes mellitusInfo
- Publication number
- UY25050A1 UY25050A1 UY25050A UY25050A UY25050A1 UY 25050 A1 UY25050 A1 UY 25050A1 UY 25050 A UY25050 A UY 25050A UY 25050 A UY25050 A UY 25050A UY 25050 A1 UY25050 A1 UY 25050A1
- Authority
- UY
- Uruguay
- Prior art keywords
- diabetes mellitus
- treatment
- compound
- insulin
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de diabetes mellitus y procesos asociados a la diabetes mellitus en un mamífero, cuyo método comprende administrar una cantidad eficaz, no tóxica y farmacéuticamente eficaz de 5-(4-(2-(N-metil-N-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona (compuesto (I)) e insulina a un mamífero con necesidad de ello. Preferiblemente, la cantidad de compuesto (I) administrado es de hasta 12 mg, especialmente cuando se administra diariamente. El método comprende o bien la co-administración de compuesto (I) e insulina, o su administración secuencial. Está indicado que el efecto particularmente beneficioso sobre le control de la glucemia proporcionado por el tratamiento de la invención es un efecto sinérgico relativo al control esperado para la suma de los efectos de los agentes activos individuales. En un aspecto preferido, el nivel de dosificación de cada uno de los agentes activos, cuando se utiliza de acuerdo con el tratamiento de la invención, será menor de lo que habría sido necesario considerando un efecto puramente aditivo sobre le control de la glucemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25050A1 true UY25050A1 (es) | 2000-09-29 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25050A UY25050A1 (es) | 1997-06-18 | 1998-06-18 | Metodo de tratamiento para diabetes mellitus |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0999837A1 (es) |
| JP (1) | JP2002504138A (es) |
| KR (1) | KR20010013843A (es) |
| CN (1) | CN1133431C (es) |
| AP (1) | AP1287A (es) |
| AR (2) | AR015894A1 (es) |
| AU (1) | AU8216398A (es) |
| BG (1) | BG104059A (es) |
| BR (1) | BR9810444A (es) |
| CA (1) | CA2294141A1 (es) |
| CO (1) | CO4940454A1 (es) |
| DZ (1) | DZ2521A1 (es) |
| EA (1) | EA004800B1 (es) |
| GB (1) | GB9712866D0 (es) |
| HU (1) | HUP0003260A3 (es) |
| ID (1) | ID23951A (es) |
| IL (1) | IL133143A0 (es) |
| IN (1) | IN189723B (es) |
| MA (1) | MA26511A1 (es) |
| NO (1) | NO996265D0 (es) |
| OA (1) | OA11517A (es) |
| PE (1) | PE104499A1 (es) |
| PL (1) | PL343123A1 (es) |
| SK (1) | SK179399A3 (es) |
| TR (1) | TR199903095T2 (es) |
| TW (1) | TW587937B (es) |
| UA (1) | UA70299C2 (es) |
| UY (1) | UY25050A1 (es) |
| WO (1) | WO1998057636A1 (es) |
| ZA (1) | ZA985237B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| BR0009934A (pt) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Produto farmacêutico |
| EP1849475A1 (en) * | 1999-06-21 | 2007-10-31 | Eli Lilly & Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
| WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| US20020198203A1 (en) * | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and a thiazolidinedione agent |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| DE60317365T2 (de) | 2002-11-08 | 2008-08-21 | F. Hoffmann-La Roche Ag | Substituierte 4-alkoxyoxazol derivate als ppar agonisten |
| US7264813B2 (en) * | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE376829T1 (de) * | 1993-09-15 | 2007-11-15 | Daiichi Sankyo Co Ltd | Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm) |
| WO1997005875A2 (en) * | 1995-08-10 | 1997-02-20 | Warner-Lambert Company | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
| KR19990045756A (ko) * | 1995-09-18 | 1999-06-25 | 윌리암 엘. 레스페스 | Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법 |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Application Discontinuation
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
-
1999
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
- 1999-12-17 NO NO996265A patent/NO996265D0/no not_active Application Discontinuation
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1133431C (zh) | 2004-01-07 |
| TW587937B (en) | 2004-05-21 |
| AR015894A1 (es) | 2001-05-30 |
| KR20010013843A (ko) | 2001-02-26 |
| IN189723B (es) | 2003-04-19 |
| EP0999837A1 (en) | 2000-05-17 |
| JP2002504138A (ja) | 2002-02-05 |
| NO996265L (no) | 1999-12-17 |
| WO1998057636A1 (en) | 1998-12-23 |
| SK179399A3 (en) | 2000-11-07 |
| BG104059A (en) | 2000-10-31 |
| HUP0003260A2 (hu) | 2001-05-28 |
| ZA985237B (en) | 2000-02-17 |
| AU8216398A (en) | 1999-01-04 |
| HUP0003260A3 (en) | 2001-12-28 |
| TR199903095T2 (xx) | 2000-08-21 |
| PL343123A1 (en) | 2001-07-30 |
| PE104499A1 (es) | 2000-01-13 |
| AR012997A1 (es) | 2000-11-22 |
| EA004800B1 (ru) | 2004-08-26 |
| ID23951A (id) | 2000-06-08 |
| AP9901718A0 (en) | 1999-12-31 |
| AP1287A (en) | 2004-06-26 |
| OA11517A (en) | 2004-02-04 |
| EA200000042A1 (ru) | 2000-08-28 |
| CO4940454A1 (es) | 2000-07-24 |
| NO996265D0 (no) | 1999-12-17 |
| BR9810444A (pt) | 2000-09-05 |
| UA70299C2 (en) | 2004-10-15 |
| MA26511A1 (fr) | 2004-12-20 |
| CN1260715A (zh) | 2000-07-19 |
| GB9712866D0 (en) | 1997-08-20 |
| DZ2521A1 (fr) | 2003-02-08 |
| IL133143A0 (en) | 2001-03-19 |
| CA2294141A1 (en) | 1998-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25050A1 (es) | Metodo de tratamiento para diabetes mellitus | |
| UY25049A1 (es) | Composiciones para tratamiento para diabetes mellitus | |
| EA200601145A1 (ru) | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов | |
| KR940006590A (ko) | 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 | |
| AR057970A2 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones | |
| CY1117668T1 (el) | Φαρμακευτικες συστασεις περιλαμβανουσες ινσουλινη συμπλοκοποιημενη με μια δικετοπιπεραζινη | |
| NO314065B1 (no) | Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes | |
| BR0014142A (pt) | Composição de vacina e método de empregar a mesma | |
| BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| DE58906232D1 (de) | Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe. | |
| AR008198A1 (es) | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
| UY25051A1 (es) | Composiciones para el tratamiento de diabetes mellitus | |
| BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase | |
| PE20001239A1 (es) | Composicion de un sensibilizador de insulina | |
| BR0111536A (pt) | Sal de tiazolidinediona para tratamento de diabetes mellitus | |
| BR0112982A (pt) | Sal tartarato de derivado de tiazolidinadiona | |
| BR0112984A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
| BR0114364A (pt) | Derivado de tiazolidinediona e seu uso como anti-diabético | |
| BR0112983A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
| TH36758A (th) | กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน | |
| TH21154B (th) | กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน | |
| TH21456B (th) | กรรมวิธีในการรักษาเบาหวานด้วยไธอะโซลิดีนไดโอนและซัลโฟนิลยูเรีย |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090526 |